EU Authorizes New COVID Vaccine From Pfizer and BioNTech
6 Articles
6 Articles
Hipra has received a marketing authorisation from the European Commission for BIMERVAX, its recombinant protein adjuvanted vaccine against covid adapted to variant XFG.1.1. The updated vaccine is authorised for active immunisation to prevent covid caused by SARS-CoV-2 in people over 12 years of age. This is the third adaptation of the Hipra vaccine against covid and comes after the opinion adopted by the Committee for Medicinal Products for Huma…
The Seoul Southern District Prosecutors' Office’s Joint Investigation Division for Financial and Securities Crimes has indicted former CEO A without detention on charges of violating the Capital Markets Act for obtaining illicit gains worth 180 million won by using undisclosed information related to Wellbiotech’s COVID-19 vaccine business. The incident occurred prior to the investment disclosure in 2021.
With only a week left until the release of its Q2 earnings report on August 4th, BioNTech investors are simultaneously digesting two diametrically opposed signals. On one hand, its partner, Bristol Myers Squibb (BMS), announced an increase in its 2026 operating expenses during its July 30th earnings call, paving the way for several key oncology projects, including Pumitamig. On the other hand, the European Commission approved the company's updat…
European Commission Greenlights Pfizer-BioNTech XFG-Adapted COVID-19 Shot for 2026-2027 Season
The European Commission has formally authorized the latest iteration of the Pfizer-BioNTech COVID-19 vaccine, a monovalent formula tuned to the XFG variant, for use across the European Union and several associated countries. The decision, announced by the companies on July 29, 2026, clears the shot for active immunization against SARS-CoV-2 in people aged six months and older. According to Pfizer and BioNTech, the update follows a May recommenda…
EU authorizes new COVID vaccine from Pfizer and BioNTech
The European Commission granted marketing authorization to Pfizer (NYSE:PFE) and BioNTech’s (NASDAQ:BNTX) 2026-2027 COVID-19 vaccine formula targeting the new XFG variant, which peaked at 74 per cent of infections globally in October 2025. Manufacturing is now underway, with the vaccine under consideration by regulatory authorities across the world. Shares of Pfizer and BioNTech have fallen by 41.25 per cent and 71.66 per cent, respectively, ove…
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
